Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge Reuters Lilly star weight-loss drug Zepbound faces coverage challenge from CVS Health Yahoo Finance Novo Nordisk announces that CVS Caremark®, the country’s largest PBM, has decided Wegovy® will be the preferred GLP-1 medicine covered for obesity on its template formularies PR Newswire CVS to boost access to … Read more
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, are widely used in the treatment of metabolic disorders, including type 2 diabetes (T2D) and obesity. These medications primarily function by enhancing insulin secretion; however, emerging evidence suggests that the effects extend beyond metabolic regulation. In this issue of the JCI, Farokhnia et al. evaluated the effects … Read more
Keeping up with the GLP-1 area is a full time job by itself. First off, you have the recent development that these drugs are no longer considered to officially be in shortage, which (in theory) closes the regulatory loophole that compounding pharmacies have been using to offer their own versions. And that is already showing … Read more
From the Supreme Court ruling against hospitals in a DSH pay formula case to five Florida hospitals suing Leapfrog over safety rankings, here are 10 recent healthcare industry lawsuits, settlements and legal developments that Becker’s has reported since April 22: 1. Gilead Sciences agreed to pay $202 million to resolve allegations that it violated the … Read more
Related Stocks: NAS:ILMN,
In today’s complex benefits landscape, employers face mounting challenges in managing healthcare costs, designing effective plans, and engaging employees. With healthcare costs projected to rise 8% in 2025—the highest increase in over a decade—many organizations are turning to data analytics to transform their approach to benefits management. Today’s Employee Benefits Challenges Employers and benefit advisors … Read more
Novo Nordisk announces that CVS Caremark®, the country’s largest PBM, has decided Wegovy® will be the preferred GLP-1 medicine covered for obesity on its template formularies PR NewswireView Full Coverage on Google News
A study from the New England Journal of Medicine found new evidence that GLP-1 drugs used for diabetes and obesity could also help people with a type of liver disease. CBS News contributor Dr. Celine Gounder explains the findings.
Read the latest issue of Works in Progress here. The gender pay gap has barely changed since the early 2000s. In the US women who work full time earn 84 percent of what men earn. Twenty years ago they earned 80 percent. One of the main reasons for this is that women spend a lot … Read more
Shares of Eli Lilly dropped in pre-market trading Thursday, as competitor Novo Nordisk secured a major win on insurance coverage of its obesity drug and as Lilly reported first-quarter earnings that fell short of what investors wanted to see. CVS Caremark, the largest pharmacy benefit manager in the U.S., announced Thursday that starting in July, … Read more